NeOnc's glioma readout shows two different results, depending on the response criteria used
The Nasdaq-listed company says its intranasal NEO100 succeeded in a 24-patient recurrent glioma study, but the protocol's own scoring method gives a far weaker figure.
NeOnc Technologies (NASDAQ: NTHI) is presenting early data on NEO100 as a positive result, but the commercial weight of the claim depends on which tumour-response yardstick is used. The company's slide material reports that the Phase 2a study cleared its main goal. The protocol-specified scoring method points to a much more modest outcome.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.